Scientists Halt FEM-PrEP Study in Africa
April 18, 2011
On Monday scientists terminated a study in Africa designed to figure out whether a daily oral dose of the antiretroviral Truvada could prevent women from becoming infected with HIV.
According to FHI, the global health organization conducting the study, early results showed no evidence that the pill was effective.
The study's premature termination disappointed AIDS activists who had high hopes for its results -- but excited others who oppose the FDA's potential approval of Truvada for this purpose.
In cased you missed it, here's the report from the New York Times.
This article was provided by Housing Works. It is a part of the publication Housing Works AIDS Issues Update. Visit Housing Works' website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.